Education
About Us
Working with TipRanks
Follow Us
Renalytix (RNLXY)
OTHER OTC:RNLXY
Top Page
Renalytix
(OTC:RNLXY)
Select Model
Select Model
Rating:35Underperform
Price Target:―
Renalytix's overall score reflects significant financial distress, negative market sentiment, and poor valuation metrics. Technical indicators suggest a bearish trend, with no immediate turnaround. Strategic restructuring and operational improvements are crucial for recovery.
Renalytix (RNLXY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.70M
Dividend YieldN/A
Average Volume (3M)126.03K
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth-1.58%
EPS Growth60.03%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding202,684,330
10 Day Avg. Volume280,744
30 Day Avg. Volume126,033
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renalytix Business Overview & Revenue Model
Company DescriptionRenalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
How the Company Makes MoneyRenalytix generates revenue primarily through the sale of its diagnostic products and services to healthcare providers, hospitals, and clinical laboratories. The company's flagship product, KidneyIntelX, is a diagnostic platform that uses machine learning algorithms to assess the risk of kidney disease progression in patients. Revenue is derived from testing fees charged for each use of the KidneyIntelX platform. Additionally, Renalytix engages in partnerships with pharmaceutical companies and healthcare organizations to leverage its technology in drug development and clinical trials, which provides additional revenue streams. Strategic collaborations and licensing agreements also contribute to the company's financial performance, supporting the broader adoption of its diagnostic solutions.
Renalytix Earnings Call Summary
Earnings Call Date:Jun 17, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook for Renalytix, with significant achievements in FDA approval, Medicare reimbursement, and revenue growth. Operational improvements and strategic partnerships further enhance their position. However, resource constraints and initial market dependency present challenges. Overall, the positive developments and growth potential outweigh the challenges.Q2-2025 Updates
Positive Updates
FDA Approval and Medicare Reimbursement
Renalytix's KidneyIntelX test received FDA approval, becoming the first-ever FDA-approved breakthrough designation prognostic test for kidney disease. It is fully Medicare reimbursed at $950 per test.
Revenue Growth and Forecast
The company set revenue forecasts of $3.2 million for the current fiscal year, rising to $8.4 million next year, and $17 million thereafter. They are confident of hitting the $3.2 million revenue target, driven by a strong pipeline and new customer acquisitions.
Cost Reduction Achievements
Renalytix achieved a 50% reduction in administrative fees and has implemented new financial controls, contributing to better financial management and cost efficiency.
Commercial Testing Volume Increase
Commercial testing volume increased to 82% from 60% in the prior period, with 95% of Medicare claims now paid in under 30 days, positively impacting cash flow.
Operational Improvements
Test turnaround time improved to under seven days from 24 days, with a significant reduction in order cancellation rate from 24% to 8%.
Strong Partnerships and Strategic Collaborations
Renalytix has established partnerships with hospital systems like ACPNY and is engaging with pharmaceutical companies for future collaborations.
Negative Updates
Small Team and Resource Limitations
The company is constrained by a small team of eight salespeople, which affects their ability to rapidly expand and scale operations.
Market Expansion Constraints
While the company has potential for international expansion, it currently lacks the resources and infrastructure to enter new markets outside the U.S.
Initial Revenue Dependency and Challenges
The company was historically reliant on Mount Sinai hospital system for testing and faced a slight dip in test sales during the ACPNY onboarding phase.
Company Guidance
During the Renalytix Investor Presentation, several key metrics and strategic goals were outlined. The company has achieved a 20% quarter-on-quarter revenue growth, with expectations to reach $3.2 million in revenue for the fiscal year, $8.4 million the following year, and $17 million subsequently. The commercial testing volume increased from 60% to 82%, with Medicare reimbursing $950 per test. Renalytix has reduced administrative fees by 50% and decreased order cancellation rates from 24% to 8%. It also improved test turnaround time to under seven days and reduced billing to insurance payment time by 65%. Additionally, Renalytix aims for a 1% U.S. market penetration, equivalent to 150,000 tests annually. The company is focusing on expanding insurance partnerships, with 52% of testing now Medicare and Medicare Advantage patients, and is investing in strategic partnerships, including with pharma companies, to enhance its competitive positioning.Renalytix Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 156.00K | 720.00K | 874.00K | 687.00K | ― |
| EBITDA | -33.09M | -45.10M | -52.69M | -33.69M | -9.77M |
| Net Income | -33.46M | -45.61M | -41.44M | -31.01M | -9.84M |
Balance Sheet | |||||
| Total Assets | 7.97M | 30.63M | 50.06M | 78.58M | 20.92M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 8.54M | 12.12M | 12.34M | 0.00 | 255.00K |
| Total Liabilities | 15.83M | 23.66M | 19.46M | 7.12M | 4.97M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -30.11M | -34.09M | -46.59M | -29.17M | -10.33M |
| Operating Cash Flow | -30.11M | -34.09M | -45.92M | -28.40M | -9.52M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Renalytix Technical Analysis
Positive
0.25
Price Trends
0.18
Positive
0.19
Positive
0.21
Positive
Market Momentum
0.03
Negative
63.90
Neutral
56.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNLXY, the sentiment is Positive. The current price of 0.25 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.18, and above the 200-day MA of 0.21, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 63.90 is Neutral, neither overbought nor oversold. The STOCH value of 56.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNLXY.
Renalytix Risk Analysis
Renalytix disclosed 91 risk factors in its most recent earnings report. Renalytix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Renalytix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $147.50B | 22.41 | 89.11% | 3.33% | 13.10% | 110.67% | |
70 Neutral | $22.38B | -84.66 | -20.32% | ― | 44.38% | 22.87% | |
63 Neutral | $682.58M | -13.55 | -4.57% | ― | 4.31% | 69.57% | |
61 Neutral | $790.95M | 14.24 | 15.79% | ― | 14.72% | ― | |
49 Neutral | $5.80B | -11.95 | -18.96% | ― | -81.18% | -69.19% | |
41 Neutral | $16.68M | -0.04 | -163.82% | ― | -25.02% | 85.08% | |
35 Underperform | $51.70M | ― | ― | ― | -1.58% | 60.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
RNLXY
Renalytix
0.26
0.05
23.81%
RMTI
Rockwell Med
1.20
-2.48
-67.39%
RNTX
Rein Therapeutics
1.14
-2.48
-68.51%
LTRN
Lantern Pharma
4.35
0.59
15.69%
GBIO
Generation Bio
6.12
-17.48
-74.07%
CNTB
Connect Biopharma Holdings
1.51
0.10
7.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.